ARCHIVES

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Pinkel, Sharp, Hausen Win GM Awards for ‘86

June 13, 1986

Sen. Brown Introduces Bill on Clinical Trials Coverage

April 3, 2009

In Brief: Senate Committee Confirms Varmus; Albertini Directs Vermont Cancer Center

November 19, 1993

FDA Approves Herceptin For HER2+ Metastatic Stomach Cancers

October 22, 2010

NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.

November 12, 2004

Call to Shift Two-Thirds Of Funds a “Rubber Number,” Bailar Says

June 6, 1997